App-Quantinova.ai

Elotuzumab can costimulate NK cell responses by engaging SLAMF7

Tatiana Pazina - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

The co-chaperone UNC45A controls cancer cell proliferation through Nek7 and centrosomal separation

Yasmeen Jilani - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

The impact of ABCB1 single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients

Ingrid Jakobsen Falk - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models

Allison E. Drew - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Glucocorticoid-mediated upregulation of stress oncoproteins: implications for prostate cancer health disparities

Leanne Woods-Burnham - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Intrahepatic cholangiocarcinoma cells can be converted into functional hepatocytes by inhibition of Wnt signaling pathway

Toshiaki Nakaoka - American Association for Cancer Research (AACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Combination of duvelisib with either ibrutinib or dexamethasone prevents mTOR-dependent feedback in aggressive B-cell lymphoma cell lines

Kerry White - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Dexamethasone

Effects of INCB052793, a selective JAK1 inhibitor, in combination with standard of care agents in human multiple myeloma (MM) cell lines and xenograft models

Eric Sanchez - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Dexamethasone suppresses cytokine-induced dual oxidase 2 (Duox2) and VEGF-A expression in human pancreatic cancer cells in vitro and pancreatic cancer growth in xenografts

Yongzhong Wu - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pancreas ductal adenocarcinoma

Dexamethasone

Genome-wide screen reveals a role for glucocorticoids in B cell development that can be exploited to improve treatment of B cell acute lymphoblastic leukemia

Miles Pufall - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Dexamethasone

Mechanisms underlying estrogen-induced inflammation in estrogen-deprived breast cancer cells

Ping Fan - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

Dexamethasone

Plitidepsin targets the GTP-bound form of eEF1A2 in cancer cells

Alejandro Losada - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Combination efficacy of the selective HDAC inhibitor ACY-241 and paclitaxel in solid tumor models

Pengyu Huang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Immunotherapy of colorectal cancer by the T-cell targeted DART protein MGD007: Cellular mechanisms of action

Paul A. Moore - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

A novel glucocorticoid receptor (GR) antagonist overcomes GR-mediated chemoresistance in triple-negative breast cancer

Nadine Jahchan - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Dexamethasone pretreatment impairs the TS inhibition-mediated flare in thymidine salvage pathway activity

Sharyn I. Katz - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Functional validation of a genome-wide association study (GWAS) SNP associated with anthracycline-induced congestive heart failure

Xi Wu - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Novel combination of Di-indolylmethane (DIM) and dexamethasone induces apoptosis in myeloma cells by modulating the telomerase activity

Raman Kumar - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Snai2 is a new target to mediate glucocorticoid signaling on breast cancer cell migration

Jun Ling - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Glucocorticoids trigger GR-mediated expression of the chemoresistance-associated oncoproteins LEDGF/p75 and Clusterin: Implications for prostate cancer health disparities

Leanne Woods-Burnham - American Association for Cancer Research (AACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Filters

4337 Abstracts